Repository logo
 
Publication

The Role of Propranolol in the Treatment of Infantile Hemangioma

dc.contributor.authorLaranjo, S
dc.contributor.authorCosta, G
dc.contributor.authorParamés, F
dc.contributor.authorFreitas, I
dc.contributor.authorMartins, JD
dc.contributor.authorTrigo, C
dc.contributor.authorPinto, MF
dc.date.accessioned2014-07-23T15:46:02Z
dc.date.available2014-07-23T15:46:02Z
dc.date.issued2014
dc.description.abstractINTRODUCTION: Infantile hemangioma (IH) is one of the most common childhood tumors. There are various medical or surgical therapeutic options, all with suboptimal results. Recently, the successful use of propranolol for involution of IH was described. We report the results of a single-center experience with this therapeutic option. OBJECTIVE: To prospectively assess the efficacy and safety of propranolol in children with infantile hemangioma. METHODS: We performed a prospective analysis of clinical data of all patients with IH referred to a pediatric cardiology center for baseline cardiovascular assessment prior to propranolol therapy. Propranolol was given at a starting dose of 1 mg/kg/day and titrated to a target dose of 2-3 mg/kg/day according to clinical response. Efficacy was assessed through a photograph-based severity scoring scale. Safety was assessed by collecting data regarding significant side effects. RESULTS: Starting in 2010, 30 patients (15 female) were referred for propranolol treatment of IH, at a median age of six months (1-63 months). The mean target propranolol dose was 2.8 mg/kg/day, with a mean duration of therapy of 12 months. All patients experienced significant reduction of IH size and volume. There were no side effects. CONCLUSIONS: In our experience propranolol appears to be a useful and safe treatment option for severe or complicated IH, achieving a rapid and significant reduction in their size. No adverse effects were observed, although until larger clinical trials are completed, potential adverse events should be borne in mind and consultation with local specialists is recommended prior to initiating treatment.por
dc.identifier.citationRev Port Cardiol. 2014 May;33(5):289-95por
dc.identifier.urihttp://hdl.handle.net/10400.17/1863
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherSociedade Portuguesa de Cardiologiapor
dc.subjectHSM CAR PEDpor
dc.subjectHemangioma/drug therapypor
dc.subjectPropranolol/therapeutic usepor
dc.subjectProspective Studies
dc.subjectTreatment Outcome
dc.titleThe Role of Propranolol in the Treatment of Infantile Hemangiomapor
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage295por
oaire.citation.startPage289por
oaire.citation.titleRevista Portuguesa de Cardiologiapor
rcaap.rightsopenAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
RPC 2014.pdf
Size:
1012.95 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: